AU1993599A - Pharmaceutical compositions comprising micelles comprising lipophilic glucocorticosteroid and only one surfactant - Google Patents

Pharmaceutical compositions comprising micelles comprising lipophilic glucocorticosteroid and only one surfactant Download PDF

Info

Publication number: AU1993599A
Authority: AU; Australia
Prior art keywords: surfactant; glucocorticosteroid; micelles; composition; aqueous medium
Prior art date: 1997-12-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU19935/99A

Other languages

English (en)

Inventor

Gabrielle Sjoquist

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

AstraZeneca AB

Original Assignee

AstraZeneca AB

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-12-22

Filing date

1998-12-22

Publication date

1999-07-12

1998-12-22 Application filed by AstraZeneca AB filed Critical AstraZeneca AB

1999-07-12 Publication of AU1993599A publication Critical patent/AU1993599A/en

Status Abandoned legal-status Critical Current

Links

239000003862 glucocorticoid Substances 0.000 title claims description 46
239000000693 micelle Substances 0.000 title claims description 36
239000004094 surface-active agent Substances 0.000 title claims description 34
239000008194 pharmaceutical composition Substances 0.000 title claims description 15
239000000203 mixture Substances 0.000 claims description 59
238000000034 method Methods 0.000 claims description 30
239000012736 aqueous medium Substances 0.000 claims description 25
-1 polyoxyethylene Polymers 0.000 claims description 23
239000002736 nonionic surfactant Substances 0.000 claims description 17
239000003814 drug Substances 0.000 claims description 16
241000124008 Mammalia Species 0.000 claims description 13
239000008180 pharmaceutical surfactant Substances 0.000 claims description 12
210000002345 respiratory system Anatomy 0.000 claims description 12
230000000172 allergic effect Effects 0.000 claims description 10
150000002148 esters Chemical class 0.000 claims description 10
208000028774 intestinal disease Diseases 0.000 claims description 10
239000012453 solvate Substances 0.000 claims description 10
229920001214 Polysorbate 60 Polymers 0.000 claims description 9
239000003795 chemical substances by application Substances 0.000 claims description 9
238000004519 manufacturing process Methods 0.000 claims description 9
229950004432 rofleponide Drugs 0.000 claims description 9
IXTCZMJQGGONPY-XJAYAHQCSA-N rofleponide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3O[C@@H](CCC)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O IXTCZMJQGGONPY-XJAYAHQCSA-N 0.000 claims description 9
150000001241 acetals Chemical group 0.000 claims description 8
IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 claims description 8
208000026935 allergic disease Diseases 0.000 claims description 7
208000027866 inflammatory disease Diseases 0.000 claims description 7
239000003963 antioxidant agent Substances 0.000 claims description 6
235000006708 antioxidants Nutrition 0.000 claims description 6
150000003839 salts Chemical class 0.000 claims description 6
ULQISTXYYBZJSJ-UHFFFAOYSA-N 12-hydroxyoctadecanoic acid Chemical compound CCCCCCC(O)CCCCCCCCCCC(O)=O ULQISTXYYBZJSJ-UHFFFAOYSA-N 0.000 claims description 5
229940114069 12-hydroxystearate Drugs 0.000 claims description 5
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 5
239000000654 additive Substances 0.000 claims description 5
235000014113 dietary fatty acids Nutrition 0.000 claims description 5
239000000194 fatty acid Substances 0.000 claims description 5
229930195729 fatty acid Natural products 0.000 claims description 5
239000008103 glucose Substances 0.000 claims description 5
238000002360 preparation method Methods 0.000 claims description 5
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 4
CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims description 4
229960000289 fluticasone propionate Drugs 0.000 claims description 4
WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 claims description 4
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 4
229920000053 polysorbate 80 Polymers 0.000 claims description 4
230000001105 regulatory effect Effects 0.000 claims description 4
KIHBGTRZFAVZRV-UHFFFAOYSA-N 2-hydroxyoctadecanoic acid Chemical class CCCCCCCCCCCCCCCCC(O)C(O)=O KIHBGTRZFAVZRV-UHFFFAOYSA-N 0.000 claims description 3
KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 claims description 3
229920001213 Polysorbate 20 Polymers 0.000 claims description 3
229920001219 Polysorbate 40 Polymers 0.000 claims description 3
150000005215 alkyl ethers Chemical class 0.000 claims description 3
229950000210 beclometasone dipropionate Drugs 0.000 claims description 3
229960002744 mometasone furoate Drugs 0.000 claims description 3
WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 claims description 3
239000003002 pH adjusting agent Substances 0.000 claims description 3
229920001983 poloxamer Polymers 0.000 claims description 3
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 3
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 3
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 3
239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 claims description 3
235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 claims description 3
239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 claims description 3
235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 claims description 3
229940101027 polysorbate 40 Drugs 0.000 claims description 3
229940113124 polysorbate 60 Drugs 0.000 claims description 3
229940068968 polysorbate 80 Drugs 0.000 claims description 3
238000003756 stirring Methods 0.000 claims description 3
239000011732 tocopherol Substances 0.000 claims description 3
101100536354 Drosophila melanogaster tant gene Proteins 0.000 claims description 2
230000003078 antioxidant effect Effects 0.000 claims description 2
235000010323 ascorbic acid Nutrition 0.000 claims description 2
229960005070 ascorbic acid Drugs 0.000 claims description 2
239000011668 ascorbic acid Substances 0.000 claims description 2
229930003799 tocopherol Natural products 0.000 claims description 2
235000019149 tocopherols Nutrition 0.000 claims description 2
QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 claims description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 3
239000008139 complexing agent Substances 0.000 claims 2
229940068977 polysorbate 20 Drugs 0.000 claims 2
229940093476 ethylene glycol Drugs 0.000 claims 1
125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 1
XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical class [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 claims 1
239000000243 solution Substances 0.000 description 16
229940079593 drug Drugs 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
150000001875 compounds Chemical class 0.000 description 6
201000010099 disease Diseases 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
208000022559 Inflammatory bowel disease Diseases 0.000 description 4
239000000725 suspension Substances 0.000 description 4
VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
208000010668 atopic eczema Diseases 0.000 description 3
229960004436 budesonide Drugs 0.000 description 3
239000003960 organic solvent Substances 0.000 description 3
150000003431 steroids Chemical class 0.000 description 3
HBXWUCXDUUJDRB-UHFFFAOYSA-N 1-octadecoxyoctadecane Chemical compound CCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCCCC HBXWUCXDUUJDRB-UHFFFAOYSA-N 0.000 description 2
SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-furoic acid Chemical compound OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 description 2
QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 2
206010009900 Colitis ulcerative Diseases 0.000 description 2
208000011231 Crohn disease Diseases 0.000 description 2
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
201000006704 Ulcerative Colitis Diseases 0.000 description 2
239000002253 acid Substances 0.000 description 2
125000000129 anionic group Chemical group 0.000 description 2
239000003833 bile salt Substances 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000000872 buffer Substances 0.000 description 2
230000000536 complexating effect Effects 0.000 description 2
239000003599 detergent Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
239000012530 fluid Substances 0.000 description 2
238000005755 formation reaction Methods 0.000 description 2
229960001664 mometasone Drugs 0.000 description 2
QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 2
239000006199 nebulizer Substances 0.000 description 2
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
229920000136 polysorbate Polymers 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000007787 solid Substances 0.000 description 2
WSWCOQWTEOXDQX-MQQKCMAXSA-M (E,E)-sorbate Chemical compound C\C=C\C=C\C([O-])=O WSWCOQWTEOXDQX-MQQKCMAXSA-M 0.000 description 1
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 description 1
IBSREHMXUMOFBB-JFUDTMANSA-N 5u8924t11h Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C(C)C)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 IBSREHMXUMOFBB-JFUDTMANSA-N 0.000 description 1
XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 description 1
239000005660 Abamectin Substances 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
125000000066 S-methyl group Chemical group [H]C([H])([H])S* 0.000 description 1
IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 1
HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
DXEXNWDGDYUITL-FXSSSKFRSA-N Tipredane Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@@](SC)(SCC)[C@@]1(C)C[C@@H]2O DXEXNWDGDYUITL-FXSSSKFRSA-N 0.000 description 1
229950008167 abamectin Drugs 0.000 description 1
229940124532 absorption promoter Drugs 0.000 description 1
125000002015 acyclic group Chemical group 0.000 description 1
239000003945 anionic surfactant Substances 0.000 description 1
239000003096 antiparasitic agent Substances 0.000 description 1
229940125687 antiparasitic agent Drugs 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
229940092705 beclomethasone Drugs 0.000 description 1
NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
229960002537 betamethasone Drugs 0.000 description 1
UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
229940093761 bile salts Drugs 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
239000003093 cationic surfactant Substances 0.000 description 1
229960003728 ciclesonide Drugs 0.000 description 1
229960003840 cortivazol Drugs 0.000 description 1
RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 description 1
239000013078 crystal Substances 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
229960001145 deflazacort Drugs 0.000 description 1
FBHSPRKOSMHSIF-GRMWVWQJSA-N deflazacort Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)=N[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O FBHSPRKOSMHSIF-GRMWVWQJSA-N 0.000 description 1
230000008021 deposition Effects 0.000 description 1
229960003957 dexamethasone Drugs 0.000 description 1
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000013583 drug formulation Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
238000010931 ester hydrolysis Methods 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
229960003469 flumetasone Drugs 0.000 description 1
WXURHACBFYSXBI-GQKYHHCASA-N flumethasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O WXURHACBFYSXBI-GQKYHHCASA-N 0.000 description 1
229960000676 flunisolide Drugs 0.000 description 1
229940043075 fluocinolone Drugs 0.000 description 1
FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 1
229960002714 fluticasone Drugs 0.000 description 1
MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
238000009472 formulation Methods 0.000 description 1
229940110710 fusidate Drugs 0.000 description 1
IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical compound O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
235000001727 glucose Nutrition 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
239000012456 homogeneous solution Substances 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000007794 irritation Effects 0.000 description 1
239000000644 isotonic solution Substances 0.000 description 1
229960002418 ivermectin Drugs 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000000155 melt Substances 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
239000012528 membrane Substances 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000000178 monomer Substances 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
239000003921 oil Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
229920001993 poloxamer 188 Polymers 0.000 description 1
229940044519 poloxamer 188 Drugs 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229940100528 polyoxyl 8 stearate Drugs 0.000 description 1
229940068965 polysorbates Drugs 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
229960005205 prednisolone Drugs 0.000 description 1
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
229960004063 propylene glycol Drugs 0.000 description 1
235000013772 propylene glycol Nutrition 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
206010039083 rhinitis Diseases 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
238000004062 sedimentation Methods 0.000 description 1
235000002639 sodium chloride Nutrition 0.000 description 1
229940075554 sorbate Drugs 0.000 description 1
229940035044 sorbitan monolaurate Drugs 0.000 description 1
229940035049 sorbitan monooleate Drugs 0.000 description 1
229940031953 sorbitan monopalmitate Drugs 0.000 description 1
229940035048 sorbitan monostearate Drugs 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
229950001669 tipredane Drugs 0.000 description 1
229960001295 tocopherol Drugs 0.000 description 1
229960005294 triamcinolone Drugs 0.000 description 1
GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
239000002888 zwitterionic surfactant Substances 0.000 description 1
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Dispersion Chemistry (AREA)
Engineering & Computer Science (AREA)
Pulmonology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AU19935/99A 1997-12-22 1998-12-22 Pharmaceutical compositions comprising micelles comprising lipophilic glucocorticosteroid and only one surfactant Abandoned AU1993599A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
SE9704833		1997-12-22
SE9704833A SE9704833D0 (sv)	1997-12-22	1997-12-22	New formulation
PCT/SE1998/002426 WO1999032089A1 (en)	1997-12-22	1998-12-22	Pharmaceutical compositions comprising micelles comprising lipophilic glucocorticosteroid and only one surfactant

Publications (1)

Publication Number	Publication Date
AU1993599A true AU1993599A (en)	1999-07-12

Family

ID=20409536

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU19935/99A Abandoned AU1993599A (en)	1997-12-22	1998-12-22	Pharmaceutical compositions comprising micelles comprising lipophilic glucocorticosteroid and only one surfactant

Country Status (20)

Country	Link
EP (1)	EP1043973A1 (et)
JP (1)	JP2001526210A (et)
KR (1)	KR20010024789A (et)
CN (1)	CN1283106A (et)
AR (1)	AR017220A1 (et)
AU (1)	AU1993599A (et)
BR (1)	BR9813811A (et)
CA (1)	CA2315782A1 (et)
EE (1)	EE200000388A (et)
HU (1)	HUP0102365A3 (et)
ID (1)	ID26945A (et)
IL (1)	IL136880A0 (et)
NO (1)	NO20003220L (et)
NZ (1)	NZ505073A (et)
PL (1)	PL341361A1 (et)
SE (1)	SE9704833D0 (et)
SK (1)	SK9532000A3 (et)
TR (1)	TR200001977T2 (et)
WO (1)	WO1999032089A1 (et)
ZA (1)	ZA9811461B (et)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE9902674D0 (sv) *	1999-07-12	1999-07-12	Astra Ab	New composition
SE0000332D0 (sv) *	2000-01-31	2000-01-31	Astrazeneca Ab	New use
US6759398B2 (en)	2000-08-05	2004-07-06	Smithkline Beecham Corporation	Anti-inflammatory androstane derivative
US6777399B2 (en)	2000-08-05	2004-08-17	Smithkline Beecham Corporation	Anti-inflammatory androstane derivative compositions
US6777400B2 (en)	2000-08-05	2004-08-17	Smithkline Beecham Corporation	Anti-inflammatory androstane derivative compositions
US6858593B2 (en)	2000-08-05	2005-02-22	Smithkline Beecham Corporation	Anti-inflammatory androstane derivative compositions
US6787532B2 (en) *	2000-08-05	2004-09-07	Smithkline Beecham Corporation	Formulation containing anti-inflammatory androstane derivatives
KR100889426B1 (ko)	2000-08-05	2009-03-23	글락소 그룹 리미티드	항염증제로서의 6.알파.,9.알파.-디플루오로-17.알파.-'(2-푸라닐카르복실)옥시-11.베타.-히드록시-16.알파.-메틸-3-옥소-안드로스트-1,4-디엔-17-카르보티오산 ｓ-플루오로메틸 에스테르
US6750210B2 (en)	2000-08-05	2004-06-15	Smithkline Beecham Corporation	Formulation containing novel anti-inflammatory androstane derivative
US6858596B2 (en)	2000-08-05	2005-02-22	Smithkline Beecham Corporation	Formulation containing anti-inflammatory androstane derivative
GB0019172D0 (en)	2000-08-05	2000-09-27	Glaxo Group Ltd	Novel compounds
SE0100901D0 (sv) *	2001-03-15	2001-03-15	Astrazeneca Ab	New composition
UA77656C2 (en)	2001-04-07	2007-01-15	Glaxo Group Ltd	S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
AU2002253342B2 (en)	2001-04-30	2007-01-04	Glaxo Group Limited	Novel anti-inflammatory androstane derivatives
GB2389530B (en)	2002-06-14	2007-01-10	Cipla Ltd	Pharmaceutical compositions
EP1661556A4 (en) *	2003-08-20	2010-05-19	Ajinomoto Kk	MEDICAL PREPARATION WITH IMPROVED RESOLUTION CHARACTERISTICS
US8497258B2 (en)	2005-11-12	2013-07-30	The Regents Of The University Of California	Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
CN100579510C (zh) *	2006-04-13	2010-01-13	新疆维吾尔自治区包虫病临床研究所	新型前体胶束制剂及其生产方法
WO2009064458A2 (en)	2007-11-13	2009-05-22	Meritage Pharma, Inc.	Compositions for the treatment of inflammation of the gastrointestinal tract
US20090143343A1 (en)	2007-11-13	2009-06-04	Meritage Pharma, Inc.	Compositions for the treatment of inflammation of the gastrointestinal tract
MX2011002688A (es) *	2008-09-12	2011-04-12	Critical Pharmaceuticals Ltd	Mejoramientos en la absorcion de agentes terapeuticos a traves de las membranas mucosas o la piel.
CN101982168B (zh) *	2010-11-02	2012-05-23	山东大学	一种槲皮素纳米胶束制剂及其制备方法
CN102793678B (zh) *	2011-05-26	2017-06-30	邓世明	一种不含吐温的多烯紫杉醇注射剂的制备方法
DE102011108948A1 (de) *	2011-07-29	2013-01-31	Achim Göpferich	Wässrige, kolloidale Lösungen von lipophilen Substanzen,insbesondere Arzneistofflösungen
JP5456802B2 (ja) *	2012-01-23	2014-04-02	株式会社Ｃａｃ	細胞遊走促進剤及び創傷治療用の経皮吸収剤
US10596115B2 (en) *	2013-07-17	2020-03-24	Council Of Scientific & Industrial Research	Pharmaceutical composition for the treatment of diminution of bone tissue
US10328087B2 (en)	2015-07-23	2019-06-25	Therapeuticsmd, Inc.	Formulations for solubilizing hormones
MX2018011705A (es)	2016-04-01	2019-06-10	Therapeuticsmd Inc	Composicion farmaceutica de hormona esteroide.
WO2017173044A1 (en)	2016-04-01	2017-10-05	Therapeuticsmd Inc.	Steroid hormone compositions in medium chain oils
KR102086316B1 (ko) *	2019-09-09	2020-03-09	한국콜마주식회사	경피흡수성이 우수한 화장료 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0179583A1 (en) *	1984-10-04	1986-04-30	Merck & Co. Inc.	A system for enhancing the water dissolution rate and solubility of poorly soluble drugs
US4994439A (en) *	1989-01-19	1991-02-19	California Biotechnology Inc.	Transmembrane formulations for drug administration
SA95160463B1 (ar) *	1994-12-22	2005-10-04	استرا أكتيبولاج	مساحيق للاستنشاق

1997
- 1997-12-22 SE SE9704833A patent/SE9704833D0/xx unknown
1998
- 1998-12-14 ZA ZA9811461A patent/ZA9811461B/xx unknown
- 1998-12-17 AR ARP980106453A patent/AR017220A1/es not_active Application Discontinuation
- 1998-12-22 AU AU19935/99A patent/AU1993599A/en not_active Abandoned
- 1998-12-22 KR KR1020007006879A patent/KR20010024789A/ko not_active Withdrawn
- 1998-12-22 TR TR2000/01977T patent/TR200001977T2/xx unknown
- 1998-12-22 IL IL13688098A patent/IL136880A0/xx unknown
- 1998-12-22 BR BR9813811-1A patent/BR9813811A/pt not_active IP Right Cessation
- 1998-12-22 ID IDW20001131A patent/ID26945A/id unknown
- 1998-12-22 WO PCT/SE1998/002426 patent/WO1999032089A1/en not_active Ceased
- 1998-12-22 SK SK953-2000A patent/SK9532000A3/sk unknown
- 1998-12-22 CN CN98812507A patent/CN1283106A/zh active Pending
- 1998-12-22 EE EEP200000388A patent/EE200000388A/et unknown
- 1998-12-22 HU HU0102365A patent/HUP0102365A3/hu unknown
- 1998-12-22 NZ NZ505073A patent/NZ505073A/xx unknown
- 1998-12-22 CA CA002315782A patent/CA2315782A1/en not_active Abandoned
- 1998-12-22 PL PL98341361A patent/PL341361A1/xx unknown
- 1998-12-22 JP JP2000525082A patent/JP2001526210A/ja active Pending
- 1998-12-22 EP EP98964662A patent/EP1043973A1/en not_active Withdrawn
2000
- 2000-06-21 NO NO20003220A patent/NO20003220L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
PL341361A1 (en)	2001-04-09
TR200001977T2 (tr)	2000-12-21
HUP0102365A2 (hu)	2001-11-28
EE200000388A (et)	2002-02-15
AR017220A1 (es)	2001-08-22
WO1999032089A1 (en)	1999-07-01
ZA9811461B (en)	1999-06-22
HUP0102365A3 (en)	2002-01-28
SK9532000A3 (en)	2000-11-07
SE9704833D0 (sv)	1997-12-22
EP1043973A1 (en)	2000-10-18
NO20003220L (no)	2000-08-22
ID26945A (id)	2001-02-22
BR9813811A (pt)	2000-10-03
CN1283106A (zh)	2001-02-07
IL136880A0 (en)	2001-06-14
KR20010024789A (ko)	2001-03-26
CA2315782A1 (en)	1999-07-01
NZ505073A (en)	2002-09-27
NO20003220D0 (no)	2000-06-21
JP2001526210A (ja)	2001-12-18

Publication	Publication Date	Title
AU1993599A (en)	1999-07-12	Pharmaceutical compositions comprising micelles comprising lipophilic glucocorticosteroid and only one surfactant
DE69928665T2 (de)	2006-08-10	Kortikosteroide enthaltende wässrige Zusammensetzungen zum nasalen oder pulmonalen Zuführen
US8455002B2 (en)	2013-06-04	Stable corticosteroid nanoparticulate formulations and methods for the making and use thereof
JP5001657B2 (ja)	2012-08-15	噴霧化用のシクレソニドの水性懸濁液
US20120022032A1 (en)	2012-01-26	Corticosteroid compositions and methods of treatments thereof
US12324811B2 (en)	2025-06-10	Intranasal formulation
US20210251903A1 (en)	2021-08-19	Preparation of Microparticulate Triamcinolone Acetonide Injectable Suspension
US8466134B1 (en)	2013-06-18	Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
KR20060012030A (ko)	2006-02-06	디아제팜을 함유하는 경비 마이크로에멀젼
CZ20002298A3 (cs)	2000-10-11	Farmaceutický prostředek, obsahující micely ve vodném prostředí, a způsob jeho přípravy
MXPA00006161A (en)	2002-02-26	Pharmaceutical compositions comprising micelles comprising lipophilic glucocorticosteroid and only one surfactant
JP3470131B2 (ja)	2003-11-25	持効性点鼻剤
CN118317771A (zh)	2024-07-09	用于局部治疗布鲁里溃疡中的溃疡分枝杆菌的制剂和方法
HK40111713A (zh)	2025-01-03	用於局部治疗布鲁里溃疡中的溃疡分枝杆菌的制剂和方法
CN120284882A (zh)	2025-07-11	氟维司群药物组合物、其制备方法及应用
HK1098486B (en)	2010-04-16	Aqueous suspensions of ciclesonide for nebulisation

Legal Events

Date	Code	Title	Description
2003-05-22	MK5	Application lapsed section 142(2)(e) - patent request and compl. specification not accepted